• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿尔茨海默病中β淀粉样蛋白斑块的分子与治疗靶点：一项综述研究

Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study.

作者信息

Thomas Jaya, Wilson Samson

机构信息

Department of Pharmacology, School of Pharmacy University of Amrita Vishwavidyapeetham, Guntur, India.

University of Amrita Vishwavidyapeetham, Coimbatore, India.

出版信息

Basic Clin Neurosci. 2024 Jan-Feb;15(1):1-26. doi: 10.32598/bcn.2021.3522.1. Epub 2024 Jan 1.

DOI:10.32598/bcn.2021.3522.1
PMID:39291090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11403107/
Abstract

Alzheimer's disease (AD) is characterized by progressive loss of cognition and a gradual decrease in memory. Although AD is considered the most persistent form of dementia and a global concern, no complete cure or agents that can completely halt the progression of AD have been found. In the past years, significant progress has been made in understanding the cellular and molecular changes associated with AD, and numerous drug targets have been identified for the development of drugs for this disease. Amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFT) are the major attributes of AD. Symptomatic relief is the only possible treatment available at present and a disease-modifying drug is of utmost importance. The development of drugs that can inhibit different targets responsible for the formation of plaques is a potential area in AD research. This review is not a complete list of all possible targets for AD but serves to highlight the targets related to Aβ pathology and pathways concerned with the formation of Aβ fragments. This shall serve as a prospect in the identification of Aβ plaque inhibitors and pave the strategies for newer drug treatments. Nevertheless, substantial research is done in this area but to bridle, the clinical difficulty remains a concern.

摘要

阿尔茨海默病（AD）的特征是认知功能进行性丧失和记忆力逐渐减退。尽管AD被认为是最常见的痴呆形式且备受全球关注，但尚未找到能完全治愈或彻底阻止AD进展的药物。在过去几年里，在理解与AD相关的细胞和分子变化方面取得了重大进展，并且已经确定了许多用于开发治疗该疾病药物的靶点。β-淀粉样蛋白（Aβ）斑块和神经原纤维缠结（NFT）是AD的主要特征。目前唯一可行的治疗方法是缓解症状，而开发改变疾病进程的药物至关重要。开发能够抑制导致斑块形成的不同靶点的药物是AD研究中的一个潜在领域。本综述并非AD所有可能靶点的完整清单，而是旨在突出与Aβ病理学相关的靶点以及与Aβ片段形成有关的途径。这将为鉴定Aβ斑块抑制剂提供前景，并为新的药物治疗策略铺平道路。然而，该领域已开展了大量研究，但要控制临床难题仍令人担忧。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/81a05e0902f3/BCN-15-1-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/937a40455f0f/BCN-15-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/473c1a544987/BCN-15-1-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/397eff481c82/BCN-15-1-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/6ccb2ff98162/BCN-15-1-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/546a622e21df/BCN-15-1-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/1436e6063145/BCN-15-1-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/fe654bbeb043/BCN-15-1-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/718b668f564b/BCN-15-1-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/55f37e41e9bd/BCN-15-1-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/81a05e0902f3/BCN-15-1-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/937a40455f0f/BCN-15-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/473c1a544987/BCN-15-1-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/397eff481c82/BCN-15-1-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/6ccb2ff98162/BCN-15-1-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/546a622e21df/BCN-15-1-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/1436e6063145/BCN-15-1-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/fe654bbeb043/BCN-15-1-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/718b668f564b/BCN-15-1-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/55f37e41e9bd/BCN-15-1-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d1/11403107/81a05e0902f3/BCN-15-1-g010.jpg

相似文献

1
Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study.阿尔茨海默病中β淀粉样蛋白斑块的分子与治疗靶点：一项综述研究
Basic Clin Neurosci. 2024 Jan-Feb;15(1):1-26. doi: 10.32598/bcn.2021.3522.1. Epub 2024 Jan 1.
2
Alzheimer's disease.阿尔茨海默病
Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14.
3
Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.阿尔茨海默病中针对β淀粉样蛋白的治疗策略
Curr Alzheimer Res. 2019;16(5):418-452. doi: 10.2174/1567205016666190321163438.
4
Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.阿尔茨海默病由在AD特异性、β-淀粉样前体蛋白（βAPP）非依赖途径中产生并在神经元内保留的β-淀粉样蛋白驱动：当前观点及未来实验模型
Ann Integr Mol Med. 2020;2(1):90-114. doi: 10.33597/aimm.02-1007.
5
A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.阿尔茨海默病的病理生理学和治疗干预的最新进展。
Curr Pharm Des. 2023;29(43):3428-3441. doi: 10.2174/0113816128264355231121064704.
6
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.纤维状 Aβ 在阿尔茨海默病小鼠模型中引发小胶质细胞蛋白质组改变和功能障碍。
Elife. 2020 Jun 8;9:e54083. doi: 10.7554/eLife.54083.
7
Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.利用先进的癌症疗法在阿尔茨海默病的临床前模型中逆转病理学：通过攻击脑血管新血管生成。
EBioMedicine. 2021 Sep;71:103503. doi: 10.1016/j.ebiom.2021.103503. Epub 2021 Sep 15.
8
[Therapy of Alzheimer disease].[阿尔茨海默病的治疗]
Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33.
9
Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.阿尔茨海默病中淀粉样蛋白、tau蛋白和微血管病变的传播：神经病理学和神经影像学研究结果
J Alzheimers Dis. 2014;42 Suppl 4:S421-9. doi: 10.3233/JAD-141461.
10
Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches.阿尔茨海默病：蛋白质在发病机制、作用机制和新治疗方法中的作用。
Neurosci Lett. 2023 Nov 20;817:137532. doi: 10.1016/j.neulet.2023.137532. Epub 2023 Oct 20.

引用本文的文献

1
A Survey on Computational Methods in Drug Discovery for Neurodegenerative Diseases.计算方法在神经退行性疾病药物发现中的应用研究综述
Biomolecules. 2024 Oct 19;14(10):1330. doi: 10.3390/biom14101330.

本文引用的文献

1
Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease.临床先例蛋白激酶：其用于神经退行性疾病的理论依据。
Front Aging Neurosci. 2020 Sep 2;12:242. doi: 10.3389/fnagi.2020.00242. eCollection 2020.
2
The involvement of NLRP3 inflammasome in the treatment of Alzheimer's disease.NLRP3 炎性小体在阿尔茨海默病治疗中的作用。
Ageing Res Rev. 2020 Dec;64:101192. doi: 10.1016/j.arr.2020.101192. Epub 2020 Oct 13.
3
Neprilysin as a Biomarker: Challenges and Opportunities.中性内肽酶作为一种生物标志物：挑战与机遇。
Card Fail Rev. 2020 Aug 14;6:e23. doi: 10.15420/cfr.2019.21. eCollection 2020 Mar.
4
The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation.新型 DYRK1A 抑制剂 KVN93 可调节认知功能、淀粉样β 病理学和神经炎症。
Free Radic Biol Med. 2020 Nov 20;160:575-595. doi: 10.1016/j.freeradbiomed.2020.08.030. Epub 2020 Sep 5.
5
Metformin Ameliorates Synaptic Defects in a Mouse Model of AD by Inhibiting Cdk5 Activity.二甲双胍通过抑制Cdk5活性改善阿尔茨海默病小鼠模型中的突触缺陷。
Front Cell Neurosci. 2020 Jun 24;14:170. doi: 10.3389/fncel.2020.00170. eCollection 2020.
6
Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model.抗人 TREM2 诱导小胶质细胞增殖并减少阿尔茨海默病模型中的病理。
J Exp Med. 2020 Sep 7;217(9). doi: 10.1084/jem.20200785.
7
A resurrection of aducanumab for Alzheimer's disease.阿杜卡单抗用于治疗阿尔茨海默病的再度兴起。
Lancet Neurol. 2020 Feb;19(2):111-112. doi: 10.1016/S1474-4422(19)30480-6. Epub 2019 Dec 4.
8
Pharmacological Inhibitors of the NLRP3 Inflammasome.NLRP3 炎性小体的药理学抑制剂。
Front Immunol. 2019 Oct 25;10:2538. doi: 10.3389/fimmu.2019.02538. eCollection 2019.
9
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.两种不同剂量的米诺环素与安慰剂治疗轻度阿尔茨海默病患者的随机临床试验。
JAMA Neurol. 2020 Feb 1;77(2):164-174. doi: 10.1001/jamaneurol.2019.3762.
10
The role of TREM2 in Alzheimer's disease; evidence from transgenic mouse models.TREM2 在阿尔茨海默病中的作用；来自转基因小鼠模型的证据。
Neurobiol Aging. 2020 Feb;86:39-53. doi: 10.1016/j.neurobiolaging.2019.09.004. Epub 2019 Sep 23.